Overexpression of p21(Cip1) or p27(Kip1) in the promyelocytic leukemia cell line HL60 accelerates its lineage-specific differentiation

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 4935-4945

  Zhou, Ping ^a   Yao, Yao ^a   Soh, Jae Won ^a   Weinstein, I Bernard ^a  

^a Columbia University ^*  (United States)

Author keywords

Cell cycle; Differentiation; p21(Cip1); p27(Kip1); Promyelocytic leukemia

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE 2; DIMETHYL SULFOXIDE; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; TETRAPROPYLAMMONIUM; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DEPHOSPHORYLATION; ENZYME ACTIVITY; GENE CONSTRUCT; GENE OVEREXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; CELL LINEAGE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINEAGE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DIMETHYL SULFOXIDE; GRANULOCYTES; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICROTUBULE-ASSOCIATED PROTEINS; MONOCYTES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TETRADECANOYLPHORBOL ACETATE; TUMOR SUPPRESSOR PROTEINS;

EID: 0033233430     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Weinstein IB, Zhou P: Cell cycle control gene defects and human cancer. Encyclopedia of Cancer 1: 256-267, 1996.
2. Hunter T, Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-82, 1994.
3. Sherr CJ: G1 phase progression: cycling on cue. Cell 79: 551-5, 1994.
4. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Dev 9: 1149-63, 1995.
5. Elledge SJ, Winston J, Harper JW: A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends in Cell Biol 6: 388-392, 1996.
6. Harper JW, Elledge SJ.: Cdk inhibitors in development and cancer. Current Opinion in Genetics & Dev, 1996.
7. El-Deiry WS, Tokino T, Velculescu VE, Levy, DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-25, 1993.
8. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707-10, 1993.
9. Cip1 CDK- interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-16, 1993.
10. Cip1 is a universal inhibitor of cyclin kinases. Nature 366: 701-4, 1993.
11. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90-8, 1994.
12. Kip1 a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
13. Cip1. Cell 78: 67-74, 1994.
14. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Dev 9: 639-49, 1995.
15. KIP2, a structually distinct member of the Cip1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Dev 9: 650-62, 1995.
16. Cip1 involved in the inhibition of Cdk kinase and PCNA. Nature, 374: 386-8, 1995.
17. Cip1. Nature, 375: 159-61, 1995.
18. Cip1/WAF1. EMBO J 14: 555-63, 1995.
19. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-7, 1993.
20. Hannon GJ, Beach D: P15INK4B is a potential effector of TGF-b-induced cell cycle arrest. Nature 371: 257-61, 1994.
21. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type Rb function. Genes & Dev 8: 2939-52, 1994.
22. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol and Cell Biol 15: 2672-81, 1995.
23. INK4. Mol Cell Biol 15: 2682-8, 1995.
24. Xiong Y, Zhang H, Beach D: D-type cyclins associated with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-14, 1992.
25. Grana X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-19, 1995.
26. Cip1 in muscle and other terminally differentiating cells. Science, 267: 1024-7, 1995.
27. Cip1, expression in the absence of p53. Oncogene 9: 3397-406, 1994.
28. Cip1(WAF-1/CIP1) during differentiation. Oncogene 9: 3389-96, 1994.
29. Cip1 by myoD. Science 267: 1018-21, 1995.
30. Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-84, 1995.
31. KIP1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes & Dev 8: 9-22, 1994.
32. Kranenburg O, Schamhorst V, Van der Eb AJ, Zantema A: Inhibition of cyclin dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131: 227-234, 1995.
33. Kip1 in the in vitro differentiation of murine keratinocytes. Cell Growth Differ 8: 203-211, 1997.
34. Kip1-defective mice. Cell 85: 733-744, 1996.
35. Kip1. Cell 85: 721-32, 1996.
36. Kip1 display increased body size, multiple organ hyperplasis, retinal dysplasis, and pituitary tumors. Cell 85: 707-720, 1996.
37. Rovera G, Santoli D, Damsky C: Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 76: 2779-2783, 1979.
38. Zhang W, Grasso L, Mcclain CD, Gambel AM, Cha Y, Salvatore T, Deisseroth AB, Mercer WE: p53-independent induction of waf1/ Cip1in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668-674, 1995.
39. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
40. Akiyama N, Sasaki H, Katoh O, Sato T, Hirai H, Yazaki Y, Sugimura T, Terada M: Increment of the cyclin D1 mRNA level in TPA-treatment of three human myeloid leukemia cell lines: HEL, CMK and HL-60 cells. Biochem Biophysical Res Comm 195: 1041-1049, 1993.
41. Horiguchi-Yamada J, Yamada H, Nakada S, Ochi K, Nemoto T: Changes of G1 cyclins, cdk2, and cyclin A during the differentiation of HL60 cells induced by TPA. Mol Cell Biochem 132: 31-37, 1994.
42. Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Research 57: 2851-2855, 1997.
43. Sherr CJ: D-type cyclins. TIBS 20: 187-90, 1995.
44. Cip1(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. Journal of Biological Chemistry 271: 31723-8, 1996.
45. Cip1 by vitamin D3 leads to the induced differentiation ofthe myelomonocytic cell line U937. Genes & Development 10: 142-53, 1996.
46. Rao SS, Chu C, Kohtz DS: Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol 14: 5259-67, 1994.
47. Skapek SX, Rhee J, Spicer DB, Lassar AB: Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase [see comments]. Science 267: 1022-4, 1995.
48. Cip1/Waf1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 280: 1069-1072, 1998.
49. Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene 18: 103-115, 1999.
50. Kiyokawa H, VMR, Rifkind RA, Marks PA: Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol 14: 7195-7203, 1994.
51. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA:Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993.
52. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-97, 1993.
53. Kato J-Y, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retiniblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes & Dev 7: 331-42, 1993.
54. Zhou P, Jiang W, Zhang Y, Kahn SM, Schieren I, Santella RM, Weinstein IB: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571-580, 1995.
55. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, Doi S, Santella RM, Weinstein IB: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8: 3447-57, 1993.